Mitsukazu Gotoh

Mitsukazu Gotoh

Auto-generated profile, based on publicly available information

Mitsukazu Gotoh

The Japanese Society of Gastroenterological Surgery Tokyo Japan

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
AKAkira Kenjo
Akira Kenjo
HMHiroaki Miyata
Hiroaki Miyata
MGMitsukazu Gotoh
Mitsukazu Gotoh
YKYukou Kitagawa
Yukou Kitagawa
MSMitsuo Shimada
Mitsuo Shimada
MMMasaki Mori
Masaki Mori
There has been no report on risk stratification for hepatectomy using a nationwide surgical database in Japan. The objective of this study was to evaluate mortality and variables associated with surgical outcomes of hepatectomy at a national level. We analyzed records of 7,732 patients who underwent hepatectomy for more than 1 segment (MOS) during 2011 in 987 different hospitals, as identified in the National Clinical Database (NCD) of Japan. The NCD captured 30-day morbidity and mortality as well as 90-day in-hospital mortality outcomes, which were submitted through a web-based data entry system. Based on 80% of the population, independent predictors for 30-day mortality and 90-day in-hospital mortality were calculated using a logistic regression model. The risk factors were validated with the remaining 20% of the cohort. The median postoperative length of hospitalization was 16.0 days. The overall patient morbidity rate was 32.1%. Thirty-day mortality and 90-day in-hospital mortality rates were 2.0% and 4.0%, respectively. Totals of 14 and 23 risk factors were respectively identified for 30-day mortality and 90-day in-hospital mortality. Factors associated with risk for 90-day in-hospital mortality were preoperative condition and comorbidity, operative indication (emergency surgery, intrahepatic/perihilar cholangiocarcinoma, or gallbladder cancer), preoperative laboratory data, and extent and location of resected segments (segment 1, 7, or 8). As a performance metric, c-indices of 30-day mortality and 90-day in-hospital mortality were 0.714 and 0.761, respectively. Here we report the first risk stratification analysis of hepatectomy using a Japanese nationwide surgical database. This system would predict surgical outcomes of hepatectomy and be useful to evaluate and benchmark performance.

24 March 2015 in Surgery Today
Verified
Journal Article
Open access
PDF file
MGMitsukazu Gotoh
Mitsukazu Gotoh
HMHiroaki Miyata
Hiroaki Miyata
HHHideki Hashimoto
Hideki Hashimoto
GWGo Wakabayashi
Go Wakabayashi
HKHiroyuki Konno
Hiroyuki Konno
TITadashi Iwanaka
Tadashi Iwanaka
The National Clinical Database (NCD) of Japan was established in April, 2010 with ten surgical subspecialty societies on the platform of the Japan Surgical Society. Registrations began in 2011 and over 4,000,000 cases from more than 4100 facilities were registered over a 3-year period. The gastroenterological section of the NCD collaborates with the American College of Surgeons’ National Surgical Quality Improvement Program, which shares a similar goal of developing a standardized surgical database for surgical quality improvement, with similar variables for risk adjustment. Risk models of mortality for eight procedures; namely, esophagectomy, partial/total gastrectomy, right hemicolectomy, low anterior resection, hepatectomy, pancreaticoduodenectomy, and surgery for acute diffuse peritonitis, have been established, and feedback reports to participants will be implemented. The outcome measures of this study were 30-day mortality and operative mortality. In this review, we examine the eight risk models, compare the procedural outcomes, outline the feedback reporting, and discuss the future evolution of the NCD.

17 May 2014 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
MHMitsunori Higuchi
Mitsunori Higuchi
HYHiroshi Yaginuma
Hiroshi Yaginuma
AYAtsushi Yonechi
Atsushi Yonechi
RKRyuzo Kanno
Ryuzo Kanno
AOAkio Ohishi
Akio Ohishi
MGMitsukazu Gotoh
Mitsukazu Gotoh
Video-assisted thoracic surgery (VATS) lobectomy is a standard treatment for lung cancer. This study retrospectively compared long-term outcomes after VATS lobectomy versus lobectomy via open thoracotomy for clinical stage IA non-small cell lung cancer (NSCLC).

11 April 2013 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HSHiroyuki Suzuki
Hiroyuki Suzuki
MFMitsuro Fukuhara
Mitsuro Fukuhara
TYTakumi Yamaura
Takumi Yamaura
SMSatoshi Mutoh
Satoshi Mutoh
NONaoyuki Okabe
Naoyuki Okabe
MGMitsukazu Gotoh
Mitsukazu Gotoh
Vaccine treatment using multiple peptides derived from multiple proteins is considered to be a promising option for cancer immune therapy, but scientific evidence supporting the therapeutic efficacy of multiple peptides is limited. We conducted phase I trials using a mixture of multiple therapeutic peptide vaccines to evaluate their safety, immunogenicity and clinical response in patients with advanced/recurrent NSCLC. We administered two different combinations of four HLA-A24-restricted peptides. Two were peptides derived from vascular endothelial growth factor receptor 1 (VEGFR1) and 2 (VEGFR2), and the third was a peptide derived from up-regulated lung cancer 10 (URLC10, which is also called lymphocyte antigen 6 complex locus K [LY6K]). The fourth peptide used was derived from TTK protein kinase (TTK) or cell division associated 1 (CDCA1). Vaccines were administered weekly by subcutaneous injection into the axillary region of patients with montanide ISA-51 incomplete Freund’s adjuvant, until the disease was judged to have progressed or patients requested to be withdrawn from the trial. Immunological responses were primarily evaluated using an IFN-gamma ELiSPOT assay. Vaccinations were well tolerated with no severe treatment-associated adverse events except for the reactions that occurred at the injection sites. Peptide-specific T cell responses against at least one peptide were observed in 13 of the 15 patients enrolled. Although no patient exhibited complete or partial responses, seven patients (47%) had stable disease for at least 2 months. The median overall survival time was 398 days, and the 1- and 2-year survival rates were 58.3% and 32.8%, respectively. Peptide vaccine therapy using a mixture of four novel peptides was found to be safe, and is expected to induce strong specific T cell responses. These studies were registered with ClinicalTrials.gov NCT00633724 and NCT00874588 .

15 November 2011 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
SKSeigo Kashimura
Seigo Kashimura
ZSZenichiro Saze
Zenichiro Saze
MTMasanori Terashima
Masanori Terashima
NSNobutoshi Soeta
Nobutoshi Soeta
SOSatoshi Ohtani
Satoshi Ohtani
MGMitsukazu Gotoh
Mitsukazu Gotoh

15 October 2010 in Transplantation
Verified
Journal Article
Closed access
TSTakuro Saito
Takuro Saito
MGMitsukazu Gotoh
Mitsukazu Gotoh
SSSusumu Satomi
Susumu Satomi
SUShinji Uemoto
Shinji Uemoto
TKTakashi Kenmochi
Takashi Kenmochi
STSatoshi Teraoka
Satoshi Teraoka
Background. This report summarizes outcomes of islet transplantation employing donors after cardiac death (DCD) between 2004 and 2007 as reported to the Japan Islet Transplantation Registry. Method. Sixty-five islet isolations were performed for 34 transplantations in 18 patients with insulin-dependent diabetes mellitus, including two patients who had prior kidney transplantation. All but one donor (64/65) was DCD at the time of harvesting. Results. Factors influencing criteria for islet release included duration of low blood pressure of the donor, cold ischemic time, and usage of Kyoto solution for preservation. Multivariate analysis selected usage of Kyoto solution as most important. Of the 18 recipients, 8, 4, and 6 recipients received 1, 2, and 3 islet infusions, respectively. Overall graft survival defined as C-peptide level more than or equal to 0.3 ng/mL was 76.5%, 47.1%, and 33.6% at 1, 2, and 3 years, respectively, whereas corresponding graft survival after multiple transplantations was 100%, 80.0%, and 57.1%, respectively. All recipients remained free of severe hypoglycemia while three achieved insulin independence for 14, 79, and 215 days. HbA1c levels and requirement of exogenous insulin were significantly improved in all patients. Conclusion. Islet transplantation employing DCD can ameliorate severe hypoglycemic episodes, significantly improve HbA1c levels, sustain significant levels of C-peptide, and achieve insulin independence after multiple transplantations. Thus, DCD can be an important resource for islet transplantation if used under strict releasing criteria and in multiple transplantations, particularly in countries where heart-beating donors are not readily available.